AWA
REGN icon

Arkadios Wealth Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Arkadios Wealth Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.25M Buy
5,205
+770
+17% +$524K 0.05% 379
2026
Q1 		$3.43M Buy
4,435
+1,184
+36% +$906K 0.06% 345
2025
Q4 		$2.51M Buy
3,251
+1,251
+63% +$850K 0.05% 385
2025
Q3 		$1.12M Sell
2,000
-40
-2% -$22.6K 0.03% 594
2025
Q2 		$1.07M Buy
2,040
+1,631
+399% +$910K 0.03% 550
2025
Q1 		$259K Buy
+409
New +$281K 0.01% 955
2024
Q3 		– Sell
-202
Closed -$212K – 967
2024
Q2 		$212K Buy
+202
New +$196K 0.01% 747
2021
Q4 		– Sell
-56
Closed -$33K – 1498
2021
Q3 		$33K Sell
56
-1
-2% -$621 ﹤0.01% 1035
2021
Q2 		$31K Buy
57
+28
+97% +$14.2K ﹤0.01% 1115
2021
Q1 		$13K Buy
29
+24
+480% +$11.7K ﹤0.01% 1109
2020
Q4 		$2K Sell
5
-11
-69% -$5.94K ﹤0.01% 1271
2020
Q3 		$9.6K Hold
16
– – ﹤0.01% 755
2020
Q2 		$10.3K Hold
16
– – 0.01% 678
2020
Q1 		$7.81K Buy
+16
New +$6.6K 0.01% 687

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Arkadios Wealth Advisors's REGN Position: Q2 2026 in Review

Arkadios Wealth Advisors increased its Regeneron Pharmaceuticals (REGN) stake by 17% in Q2 2026, buying an estimated $524K and bringing the position to 5,205 shares worth $3.25M. The position accounts for 0.05% of the portfolio, ranked #379.

Arkadios Wealth Advisors first reported a position in REGN in Q1 2020 and has held it in 14 quarters since. The position peaked at $3.43M in Q1 2026. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Arkadios Wealth Advisors held 5,205 shares of Regeneron Pharmaceuticals worth $3.25M as of Q2 2026.
  • Arkadios Wealth Advisors bought 770 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $524K.
  • Regeneron Pharmaceuticals made up 0.05% of Arkadios Wealth Advisors's portfolio in Q2 2026, its #379 holding.
  • Arkadios Wealth Advisors first reported a position in Regeneron Pharmaceuticals in Q1 2020 and has held it in 14 quarters since.
  • Arkadios Wealth Advisors's Regeneron Pharmaceuticals position peaked at $3.43M in Q1 2026.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Arkadios Wealth Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.